Bioequivalence Study of Sertraline 100 mg Tablet and ZOLOFT Following a 100 mg Dose in Healthy Subjects Under Fasting Conditions
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To compare the rate and extent of absorption of Torrent Pharmaceuticals Limited, India, sertraline and Pfizer, Inc., USA (Zoloft) sertraline, administered as a 1X100 mg tablet, under fasted conditions.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Male or female, smoker or non smoker, 18 years of age and older.
Capable of consent.
BMI>= 19.0 and <30.0 kg/m2
Subjects to whom any of the following applies will be excluded from the study:
Clinically significant illness or surgery within 4 weeks prior to the administration of the study medication.
Positive testing for hepatitis B, hepatitis C, or HIV at screening.
ECG abnormalities or vital sign abnormalities(blood pressure).
History of significant alcohol or drug abuse within one year prior to the screening visit.
History or allergic reactions to heparin, sertraline or other related drugs.
Use of an investigational drug or participation in an investigational study with in 30 days prior to administration of the study medication.
Clinically significant history of gastrointestinal pathology, liver or kidney disease, neurological, cardiovascular, pulmonary, hematologic, immunologic, psychiatric or metabolic disease.
History of seizures, suicide attempt, bipolar disorder or manic episodes.
Depot injection or an implant of any drugs with in 6 months prior to administration of study medication.
Positive urine pregnancy test at screening.
female subject of child bearing potential having unprotected sexual intercourse with any non-sterile mail partner within 14 days prior to study drug administration.
Acceptable methods of contraception:
Intra-uterine contraceptive device(placed at least 4 weeks prior to study drug administration)